Cargando…

Comorbidity and survival among women with ovarian cancer: evidence from prospective studies

The relationship between comorbidity and ovarian cancer survival has been controversial so far. Therefore, we conducted a meta-analysis to summarize the existing evidence from prospective studies on this issue. Relevant studies were identified by searching the PubMed, EMBASE, and ISI Web of Science...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Yi-Sheng, Gong, Ting-Ting, Wang, Yong-Lai, Wu, Qi-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484350/
https://www.ncbi.nlm.nih.gov/pubmed/26118971
http://dx.doi.org/10.1038/srep11720
_version_ 1782378647095607296
author Jiao, Yi-Sheng
Gong, Ting-Ting
Wang, Yong-Lai
Wu, Qi-Jun
author_facet Jiao, Yi-Sheng
Gong, Ting-Ting
Wang, Yong-Lai
Wu, Qi-Jun
author_sort Jiao, Yi-Sheng
collection PubMed
description The relationship between comorbidity and ovarian cancer survival has been controversial so far. Therefore, we conducted a meta-analysis to summarize the existing evidence from prospective studies on this issue. Relevant studies were identified by searching the PubMed, EMBASE, and ISI Web of Science databases through the end of January 2015. Two authors independently performed the eligibility evaluation and data abstraction. Random-effects models were used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival. Eight prospective studies involving 12,681 ovarian cancer cases were included in the present study. The summarized HR for presence versus absence of comorbidity was 1.20 (95% CI = 1.11–1.30, n = 8), with moderate heterogeneity (I(2) = 31.2%, P = 0.179). In addition, the summarized HR for the highest compared with the lowest category of the Charlson’s comorbidity index was 1.68 (95% CI = 1.50–1.87, n = 2), without heterogeneity (I(2) = 0%, P = 0.476). Notably, a significant negative impact of comorbidity on ovarian cancer survival was observed in most subgroup analyses stratified by the study characteristics and whether there was adjustment for potential confounders. In conclusion, the findings of this meta-analysis suggest that underlying comorbidity is consistently associated with decreased survival in patients with ovarian cancer. Comorbidity should be taken into account when managing these patients.
format Online
Article
Text
id pubmed-4484350
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44843502015-07-08 Comorbidity and survival among women with ovarian cancer: evidence from prospective studies Jiao, Yi-Sheng Gong, Ting-Ting Wang, Yong-Lai Wu, Qi-Jun Sci Rep Article The relationship between comorbidity and ovarian cancer survival has been controversial so far. Therefore, we conducted a meta-analysis to summarize the existing evidence from prospective studies on this issue. Relevant studies were identified by searching the PubMed, EMBASE, and ISI Web of Science databases through the end of January 2015. Two authors independently performed the eligibility evaluation and data abstraction. Random-effects models were used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival. Eight prospective studies involving 12,681 ovarian cancer cases were included in the present study. The summarized HR for presence versus absence of comorbidity was 1.20 (95% CI = 1.11–1.30, n = 8), with moderate heterogeneity (I(2) = 31.2%, P = 0.179). In addition, the summarized HR for the highest compared with the lowest category of the Charlson’s comorbidity index was 1.68 (95% CI = 1.50–1.87, n = 2), without heterogeneity (I(2) = 0%, P = 0.476). Notably, a significant negative impact of comorbidity on ovarian cancer survival was observed in most subgroup analyses stratified by the study characteristics and whether there was adjustment for potential confounders. In conclusion, the findings of this meta-analysis suggest that underlying comorbidity is consistently associated with decreased survival in patients with ovarian cancer. Comorbidity should be taken into account when managing these patients. Nature Publishing Group 2015-06-29 /pmc/articles/PMC4484350/ /pubmed/26118971 http://dx.doi.org/10.1038/srep11720 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Jiao, Yi-Sheng
Gong, Ting-Ting
Wang, Yong-Lai
Wu, Qi-Jun
Comorbidity and survival among women with ovarian cancer: evidence from prospective studies
title Comorbidity and survival among women with ovarian cancer: evidence from prospective studies
title_full Comorbidity and survival among women with ovarian cancer: evidence from prospective studies
title_fullStr Comorbidity and survival among women with ovarian cancer: evidence from prospective studies
title_full_unstemmed Comorbidity and survival among women with ovarian cancer: evidence from prospective studies
title_short Comorbidity and survival among women with ovarian cancer: evidence from prospective studies
title_sort comorbidity and survival among women with ovarian cancer: evidence from prospective studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484350/
https://www.ncbi.nlm.nih.gov/pubmed/26118971
http://dx.doi.org/10.1038/srep11720
work_keys_str_mv AT jiaoyisheng comorbidityandsurvivalamongwomenwithovariancancerevidencefromprospectivestudies
AT gongtingting comorbidityandsurvivalamongwomenwithovariancancerevidencefromprospectivestudies
AT wangyonglai comorbidityandsurvivalamongwomenwithovariancancerevidencefromprospectivestudies
AT wuqijun comorbidityandsurvivalamongwomenwithovariancancerevidencefromprospectivestudies